



Chlorion Pharma Welcomes Dr. David Lowe to its Scientific Advisory Board

LAVAL, QC, June 26 -- Chlorion Pharma Inc. today announced that Dr. David Lowe will be serving on the company's Scientific Advisory Board effective immediately.

Dr. Jeffrey Coull, Chlorion's President & CEO, expressed the company's enthusiasm to work with a pharmaceutical scientist with as much experience as Dr. Lowe, adding that "there are few individuals in the world that possess a broader and deeper knowledge of drug discovery and development than David. Chlorion is truly fortunate to be able to benefit from the insights of him".

Dr. Lowe brings more than 25 years of experience in pharmaceutical drug discovery and product development and an established track record of generating diverse clinical candidates. He most recently served as CSO and member of the Board of Directors at Memory Pharmaceuticals, which was acquired by Hoffman-La Roche Inc. Before that, he served as Executive Vice President and Chief Scientific Officer of Fidelity Biosciences and as the President and Chief Executive Officer of EnVivo Pharmaceuticals Inc. Dr. Lowe has held senior Neuroscience R&D positions in three large pharmaceutical companies, including with Sandoz Ltd (now Novartis), Bayer AG, and Roche Bioscience, where he served as the Vice President and Therapeutic Area Head, CNS.

Dr. Lowe joins Drs. Yves De Koninck, Franz Hefti, John Andrews and Terry Doyle on Chlorion's Scientific Advisory Board.

About the Company

Chlorion Pharma Inc. is a biopharmaceutical company focused on neurotherapeutics that act via the modulation of chloride in the central nervous system. Presently, the company is developing first-in-class therapeutics for the treatment of neuropathic pain and epilepsy.

For more information, please visit our website at www.chlorion.com.

##